Rain Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Selling, General & Admin	19.07	15.74	10.74	3.59	3.54
Research & Development	54.7	61.4	40.77	15.37	7.29
Other Operating Expenses	2.84	0	0	0	0
Operating Expenses	76.61	77.14	51.51	18.96	10.83
Operating Income	-76.61	-77.14	-51.51	-18.96	-10.83
Interest Expense / Income	0	0	0	0.14	0.03
Other Expense / Income	-4.35	-1.42	-0.12	1.99	0.04
Pretax Income	-72.26	-75.72	-51.39	-21.08	-10.9
Income Tax	0	0	0	0	0
Net Income	-72.26	-75.72	-51.39	-21.08	-10.9
Shares Outstanding (Basic)	36	28	19	3	2
Shares Outstanding (Diluted)	36	28	19	3	2
Shares Change	36.93%	44.21%	478.96%	38.57%	-
EPS (Basic)	-2.07	-2.71	-2.65	-6.29	-4.51
EPS (Diluted)	-2.07	-2.71	-2.65	-6.29	-4.51
Free Cash Flow	-66.45	-63.21	-37.59	-11.26	-11.33
Free Cash Flow Per Share	-1.83	-2.26	-1.94	-3.36	-4.68
EBITDA	-72.05	-75.64	-51.32	-20.9	-10.84
Depreciation & Amortization	0.21	0.08	0.07	0.05	0.03
EBIT	-72.26	-75.72	-51.39	-20.95	-10.87

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).